In 31 patients with platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma progressing on nivolumab, adding ipilimumab gave 0% response vs 17.6% with docetaxel; median PFS was shorter (1.97 vs 3.66 months), but grade ≥3 events fewer (38.5% vs 68.8%).
RCTn = 31
Grünwald et al. OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117)